Evidence map›Paper›PMID 42099999›Full record

ArticleMaterials today. Bio2026

Treatment of heterotopic ossification via inhibiting the MMP-2/CDH5 axis through oral delivery of network pharmacology-predicted Chinese medicine.

Junchao Huang, Jinxi An, Le He, Huajun Wang, Jiachang Hong, Ziheng Bu, Xudong Zhang, Wei Liu, Tingyu Wu, Seng Wang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Junchao HuangDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Jinxi AnDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Le HeSchool of Materials Science and Engineering, East China University of Science and Technology, Shanghai, 200237, PR China.
Huajun WangDepartment of Sports Medicine, The First Affiliated Hospital, The Guangzhou Key Laboratory of Precision Orthopedics and Regenerative Medicine, Guangdong Provincial Key Laboratory of Speed Capability, Jinan University, Guangzhou, Guangdong, 510630, PR China.
Jiachang HongDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Ziheng BuDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Xudong ZhangDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Wei LiuDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Tingyu WuDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Seng WangDepartment of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, PR China.
Wei ZhuDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Yuhui LiDepartment of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, PR China.
Jixian WanDepartment of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, PR China.
Min SunSchool of Materials Science and Engineering, East China University of Science and Technology, Shanghai, 200237, PR China.
Jianzhong DuDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.
Peng WuDepartment of Sports Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterotopic ossification (HO) is characterized by ectopic bone formation in soft tissues such as tendons, with an incidence exceeding 30% in high-risk populations. Currently, no targeted therapeutic options are available. In this study, matrix metalloproteinase-2 (MMP-2) was identified as a critical promoter of HO by mediating the degradation of vascular endothelial Cadherin 5 (CDH5), thereby enhancing vascular permeability and facilitating inflammatory cell infiltration. Through network pharmacology analysis, Forsythoside A (FA), a compound derived from the traditional Chinese medicine

Indexed as

Forsythoside AHeterotopic ossificationMatrix Metalloproteinase-2Network pharmacologyOral hydrogel

Identifiers

PMID42099999
PMCPMC13145377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.